Targeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer

TL;DR

This paper explores how gut microbes might influence pancreatic cancer treatment by shaping the tumor's immune environment.

Contribution

The paper introduces new insights into gut microbiota's role in pancreatic cancer immunotherapy and potential strategies to improve treatment.

Findings

Gut microbiota may migrate to the pancreas and influence the tumor microenvironment.

Changes in tumor-associated microbiota correlate with prognosis and treatment response.

Microbiome-based strategies could enhance personalized cancer treatment.

Abstract

With advances in microbial sequencing technology, the role of microorganisms in cancer development and treatment has been increasingly explored. The gut microbiota, as a key shaper of both innate and adaptive immunity, is believed to migrate from the gut and colonize the pancreas, thereby influencing the tumor microenvironment(TME) of pancreatic cancer. Pancreatic cancer exhibits treatment resistance due to its immunosuppressive TME and high interstitial density. Multiple sequencing analyses of pancreatic tumor tissues have revealed that alterations in the tumor-associated microbiota are associated with prognosis and treatment response, suggesting that the microbiota may serve as a complementary modality in immunotherapy. This paper describes potential pathways by which the gut microbiota can migrate to the pancreas and analyzes changes in tumor microbiota composition. It also identifies microbiota types associated with prognosis, and summarizes treatment strategies leveraging the gut-pancreas axis to enhance the personalization and precision of care. It critically examines the limitations of existing research, and aims to leverage microbiome ecology to overcome the immune -suppressive barrier in pancreatic cancer and improve patient outcomes.

Figures